-
Posted by
Two Blokes Jul 3 -
Filed in
Stock
-
4 views
BEIJING, SHANGHAI and BOSTON , July 2, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB-8263 for the treatment of autoimmune diseases to the Center for Drug Evaluation (CDE) in China and has been accepted. According to new regulatory guidelines, the review of JAB-8263's IND application is expected to be completed within 30 working days Dr. Yinxiang Wang, Chairman and CEO of Jacobio, said: "Autoimmune diseases affect 5%-9% of the global population.
